Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the transaction, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total transaction of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $102.39, for a total transaction of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Trading Down 0.5 %

Moderna stock traded down $0.59 during trading hours on Friday, hitting $125.00. The company had a trading volume of 4,512,362 shares, compared to its average volume of 4,144,759. The firm has a market cap of $47.86 billion, a P/E ratio of -10.07 and a beta of 1.57. The company has a 50-day moving average price of $104.47 and a two-hundred day moving average price of $94.14. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $142.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.19 EPS. On average, sell-side analysts anticipate that Moderna, Inc. will post -7.51 earnings per share for the current year.

Analysts Set New Price Targets

MRNA has been the subject of a number of research reports. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Royal Bank of Canada raised their target price on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Friday. HSBC reaffirmed a “reduce” rating and set a $86.00 price target (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer boosted their target price on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $129.55.

Institutional Trading of Moderna

Hedge funds have recently bought and sold shares of the stock. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna in the 4th quarter worth $27,000. Arlington Trust Co LLC raised its stake in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in Moderna in the first quarter worth about $32,000. Rise Advisors LLC grew its stake in shares of Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares during the last quarter. Finally, UMB Bank n.a. increased its holdings in shares of Moderna by 121.8% during the first quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after acquiring an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.